Cyclophosphamide versus placebo in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.The New England journal of medicine. 2006, Vol 354, Num 25, pp 2655-2666, issn 0028-4793, 12 p.Article

Bosentan in pulmonary arterial hypertension secondary to sclerodermaJOGLEKAR, Amit; TSAI, Fausan S; MCCLOSKEY, Deborah A et al.Journal of rheumatology. 2006, Vol 33, Num 1, pp 61-68, issn 0315-162X, 8 p.Article

Preferential expression of matrix metalloproteinase-9 in mouse skin after sulfur mustard exposureSHAKARJIAN, Michael P; BHATT, Pinaki; RILEY, David J et al.Journal of applied toxicology. 2006, Vol 26, Num 3, pp 239-246, issn 0260-437X, 8 p.Article

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.American journal of respiratory and critical care medicine. 2007, Vol 176, Num 10, pp 1026-1034, issn 1073-449X, 9 p.Article

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease : Results from the scleroderma lung studyKHANNA, Dinesh; XIAOHONG YAN; RILEY, David J et al.Arthritis and rheumatism. 2007, Vol 56, Num 5, pp 1676-1684, issn 0004-3591, 9 p.Article

Ultrahigh-resolution spin-echo measurement of surface potential energy landscapesJARDINE, Andrew P; DWORSKI, Shechar; FOUQUET, Peter et al.Science (Washington, D.C.). 2004, Vol 304, Num 5678, pp 1790-1793, issn 0036-8075, 4 p.Article

Helium detection via field ionization from carbon nanotubesRILEY, David J; MANN, Mark; MACLAREN, Donald A et al.Nano letters (Print). 2003, Vol 3, Num 10, pp 1455-1458, issn 1530-6984, 4 p.Article